Lyell Immunopharma (LYEL) Earnings Analysis
Lyell Immunopharma (LYEL) has no confirmed upcoming earnings date. Last quarter (2026-03-12) it missed with EPS -7.68 USD vs -2.15 USD est (-257.2%). It has beaten estimates in 1/3 recent quarters (33%). Trailing P/E -0.76.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does LYEL next report earnings?
No confirmed upcoming earnings date is currently scheduled for LYEL. This page updates as the calendar is published.
LYEL earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-12 | -7.68 USD | -2.15 USD | -257.2% | Miss |
| 2025-03-11 | -0.72 USD | -0.18 USD | -300% | Miss |
| 2024-11-07 | -0.17 USD | -0.2 USD | +15% | Beat |
Beat rate: 1/3 (33%) over reported quarters with consensus data.
LYEL valuation and analyst view
| Trailing P/E | -0.76 |
|---|---|
| Trailing EPS | -11.26376 USD |
| Price / book | 1.03 |
| Dividend yield | 0.00% |
| Market cap | 0.31B |
| Analyst consensus | Buy (3 buy / 3 hold / 1 sell) |
| Avg price target | 47 USD |
Related research pages
Frequently asked questions
When is Lyell Immunopharma (LYEL)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for LYEL. This page updates as the calendar is published.
Did LYEL beat earnings last quarter?
In its 2026-03-12 report, LYEL posted EPS of -7.68 USD versus a -2.15 USD estimate — a miss of 257.2%.
What is LYEL's earnings track record?
Over the last 3 reported quarters with consensus data, LYEL beat estimates 1 times (33%).
What is LYEL's current P/E ratio and EPS?
LYEL trades at a trailing P/E of -0.76 on trailing EPS of -11.263759371000182 USD.
What do analysts rate LYEL?
Analyst consensus is "Buy" across 7 ratings (0 strong buy, 3 buy, 3 hold, 1 sell, 0 strong sell). Average 12-month price target: 47 USD.